
MB-105 is a first-in-class CD5-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory CD5-positive T-cell lymphoma.

MB-105 is a first-in-class CD5-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory CD5-positive T-cell lymphoma.

Isatuximab is a CD38-targeting monoclonal antibody that has demonstrated significant clinical success in improving minimal residual disease rates and progression-free survival.

The authors note that transferrin saturation levels may be a modifiable risk factor of chronic kidney disease (CKD) progression and all-cause mortality.

Gender-affirming care and inclusive practices are essential for health equity.

In 2025, medically integrated dispensing pharmacies face significant challenges, including low reimbursements, restrictive pharmacy benefit manager practices, complex therapies, regulatory barriers such as the Stark delivery law, and the Inflation Reduction Act's financial implications, necessitating urgent advocacy, reform, and collaboration to sustain equitable, patient-centered cancer care.

Pharmacists can have informed discussions with patients about the importance of adherence to tuberculosis (TB) treatment regimens, especially for patients with active TB.

The authors note that this may cause disruptions in the metabolic stability of lipid processing and storage, impacting the liver and accelerating damaging adaptative responses.

Endocrine therapy in combination with CDK4/6 inhibitors improves patients’ outcomes, but many still become treatment resistant.

Pharmacist-led interventions significantly improve antibiotic prescribing practices, optimize therapy, and improve patient outcomes.

The trial meets one of the study’s dual primary endpoints of progression-free survival, but did not meet its other primary endpoint of overall survival.

Fractyl Health also reports progress from the REMAIN-1 study evaluating weight management after discontinuing a GLP-1.

This case study underscores the critical importance of pharmacists who can provide comprehensive consideration and exploration of the appropriate treatment plan.

Challenges include therapy gaps, nonadherence, and fragmented care.

The antibody-drug conjugate shows efficacy in reducing disease progression risk and increasing progression-free survival in patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer.

Kiles explores the impact of pharmacy research on health equity and education.

The cobas liat system is a closed system that aims to reduce contamination risks and enhances the reliability of results at the point of care.

Antiviral treatments for respiratory viruses such as respiratory syncytial virus (RSV) are crucial, especially with the rise of the "triple-demic."

Although the research focused on Black communities in the United States, there is also evidence linking racism and blood pressure for patients who are Asian or Hispanic.

Axatilimab-csfr is a colony-stimulating factor-1 receptor (CSFR1) blocking monoclonal antibody indicated for cGVHD after 2 or more lines of prior therapy in adults and pediatric patients that weigh at least 40 kg.

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.

Digital therapeutics (DTx), a novel evidence-based software approach, is revolutionizing health care by delivering personalized treatments. Pharmacovigilance ensures DTx safety but faces challenges such as data privacy and standardization.

Inhaling smoke can have acute effect for people with asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis.

Tucatinib is an oral HER2-targeting tyrosine kinase inhibitor that was approved by the FDA in 2020.

Presence of comorbidities in older patients with breast cancer complicates treatment decisions.

Rates of invasive breast cancer or death were 50% lower with adjuvant trastuzumab emtansine compared with trastuzumab alone.

Pharmacists can play an important role in tobacco cessation.

Biosimilar use is not linked to an increased risk of treatment failure among pediatric patients with inflammatory bowel disease (IBD).

Endocrine-immune-based therapies yielded favorable objective response rates but had limited impact on pathological complete response.

These data suggest the potential efficacy of immune checkpoint inhibitors with anthracycline-based chemotherapy.

Point-of-care testing implementation could provide valuable data on community respiratory syncytial virus incidence and enhance sentinel surveillance efforts.